You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

VECURONIUM BROMIDE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Vecuronium Bromide, and when can generic versions of Vecuronium Bromide launch?

Vecuronium Bromide is a drug marketed by Eugia Pharma, Gland, Hikma, Hospira, Meitheal, Mylan Labs Ltd, Sagent Pharms Inc, Sun Pharm, and Watson Labs. and is included in twelve NDAs.

The generic ingredient in VECURONIUM BROMIDE is vecuronium bromide. There are six drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the vecuronium bromide profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Vecuronium Bromide

A generic version of VECURONIUM BROMIDE was approved as vecuronium bromide by MEITHEAL on August 25th, 1999.

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for VECURONIUM BROMIDE?
  • What are the global sales for VECURONIUM BROMIDE?
  • What is Average Wholesale Price for VECURONIUM BROMIDE?
Drug patent expirations by year for VECURONIUM BROMIDE
Recent Clinical Trials for VECURONIUM BROMIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Fudan UniversityPhase 4
The Second Affiliated Hospital of Harbin Medical UniversityPhase 4
Ningbo No. 1 HospitalPhase 4

See all VECURONIUM BROMIDE clinical trials

Pharmacology for VECURONIUM BROMIDE
Medical Subject Heading (MeSH) Categories for VECURONIUM BROMIDE

US Patents and Regulatory Information for VECURONIUM BROMIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eugia Pharma VECURONIUM BROMIDE vecuronium bromide INJECTABLE;INJECTION 206670-001 Dec 20, 2018 AP RX No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Sagent Pharms Inc VECURONIUM BROMIDE vecuronium bromide INJECTABLE;INJECTION 078274-001 Dec 29, 2008 AP RX No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Hikma VECURONIUM BROMIDE vecuronium bromide INJECTABLE;INJECTION 203725-001 Jul 30, 2019 AP RX No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Gland VECURONIUM BROMIDE vecuronium bromide INJECTABLE;INJECTION 205390-002 May 26, 2016 AP RX No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Hospira VECURONIUM BROMIDE vecuronium bromide INJECTABLE;INJECTION 075164-001 Oct 21, 1999 AP RX No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

VECURONIUM BROMIDE Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Vecuronium Bromide

Introduction to Vecuronium Bromide

Vecuronium bromide is an FDA-approved, peripherally acting, monoquarternary, steroidal, non-depolarizing neuromuscular blocker. It is widely used during general anesthesia to facilitate endotracheal intubation and surgical relaxation, and in intensive care settings to achieve paralysis for mechanical ventilation in appropriately sedated patients[2].

Market Size and Growth

The global vecuronium bromide market has been experiencing significant growth. As of 2023, the market size was valued at several million dollars, and it is anticipated to grow at a compound annual growth rate (CAGR) from 2024 to 2031. This growth is driven by increasing demand in various medical sectors, particularly in surgery and intensive care[1][4].

Market Segmentation

By Type

The vecuronium bromide market is segmented based on the purity of the compound, primarily into two categories: ≥ 98% and < 98%. The ≥ 98% segment accounted for a noticeable share of the global market in 2023 and is projected to experience significant growth in the near future[1][4].

By Application

The primary applications of vecuronium bromide include surgery and tracheal intubation. The medicine segment, which encompasses these applications, is expected to expand at a significant CAGR throughout the forecast period[4].

Key Drivers

Increasing Demand in Medical Sectors

The demand for vecuronium bromide is increasing due to its critical role in surgical procedures and intensive care. The need for effective neuromuscular blockers to facilitate endotracheal intubation and surgical relaxation drives the market growth[2].

Technological Advancements

Technological advancements in the production of high-quality chemicals are a significant driver. Manufacturers are focusing on improving the purity and efficacy of vecuronium bromide, which enhances its market appeal[1].

Regulatory Environment

Environmental and safety regulations play a crucial role in shaping the chemical industry. Compliance with these regulations ensures the safe production and distribution of vecuronium bromide, supporting market growth[1].

Restraints and Challenges

Raw Material Availability

The availability of raw materials can be a restraint. Fluctuations in the supply of necessary chemicals can impact production and pricing[1].

Economic Conditions

Economic conditions, including inflation and global economic downturns, can affect the market. These factors can influence the purchasing power of healthcare institutions and the overall demand for vecuronium bromide[1].

Regulatory Changes

Changes in regulatory policies can also pose challenges. Stricter regulations or changes in approval processes can impact the production and distribution of vecuronium bromide[1].

Opportunities

Expanding Healthcare Infrastructure

The expansion of healthcare infrastructure, particularly in emerging markets, presents significant opportunities for growth. Increasing access to healthcare services in these regions drives the demand for essential medical drugs like vecuronium bromide[1].

Research and Development

Continuous research and development in the field of neuromuscular blockers offer opportunities for innovation. Improving the efficacy and safety of vecuronium bromide can further enhance its market position[2].

Competitive Landscape

The vecuronium bromide market is highly competitive, with several key players dominating the landscape. These include:

  • Jiupai Group
  • Credit Chemwerth Pharmaceutical
  • Beijing Xinze Medical Technology
  • Xianju Pharma
  • Jiangsu Nhwa Pharmaceutical
  • Curia
  • Teva API[1][4].

These companies are focusing on strategy building, product portfolio expansion, and technological advancements to strengthen their market positions.

Regional Analysis

The market is analyzed across various regions, including North America, Europe, Asia-Pacific, South America, and the Middle East & Africa. Each region has its unique market dynamics, driven by local healthcare needs, regulatory environments, and economic conditions.

  • North America: This region is characterized by advanced healthcare infrastructure and stringent regulatory standards, which influence the market dynamics.
  • Europe: Similar to North America, Europe has a well-developed healthcare system and strict regulations.
  • Asia-Pacific: This region is experiencing rapid growth due to expanding healthcare infrastructure and increasing demand for medical services.
  • South America and Middle East & Africa: These regions offer growth opportunities due to improving healthcare access and infrastructure[1].

Financial Trajectory

Revenue and Volume Forecast

The global vecuronium bromide market is expected to witness significant revenue growth from 2024 to 2031. The market value is forecasted to increase substantially, driven by the increasing demand and expanding applications of vecuronium bromide[1][4].

Company Share and Competitive Landscape

The competitive landscape is expected to remain dynamic, with key players competing to increase their market share. Companies are investing in research and development, and strategic partnerships to enhance their product portfolios and market presence[1][4].

Growth Factors and Trends

The market is influenced by several growth factors, including technological advancements, increasing healthcare expenditure, and the expanding need for neuromuscular blockers in surgical and intensive care settings. Trends such as the adoption of high-quality and environmentally friendly products are also driving the market forward[1].

Technological Trends

Technological advancements in the production of vecuronium bromide are crucial for market growth. Improvements in manufacturing processes and the development of higher purity products are key trends. For instance, the focus on producing vecuronium bromide with purity levels above 98% is a significant technological trend[1][4].

Environmental and Safety Regulations

Environmental and safety regulations are vital in shaping the vecuronium bromide market. Compliance with these regulations ensures the safe production, distribution, and use of the drug. Manufacturers must adhere to strict guidelines to maintain market approval and consumer trust[1].

COVID-19 Impact

The COVID-19 pandemic had a mixed impact on the vecuronium bromide market. While the pandemic disrupted supply chains and affected production, the increased need for critical care services also boosted the demand for neuromuscular blockers like vecuronium bromide. The market has been recovering and is expected to continue growing as healthcare systems normalize[1].

Key Takeaways

  • Market Growth: The global vecuronium bromide market is expected to grow significantly from 2024 to 2031, driven by increasing demand in medical sectors.
  • Segmentation: The market is segmented by type (≥ 98% and < 98%) and application (surgery and tracheal intubation).
  • Key Drivers: Increasing demand, technological advancements, and regulatory compliance are key drivers.
  • Competitive Landscape: The market is competitive with several key players focusing on strategy building and product portfolio expansion.
  • Regional Analysis: The market dynamics vary across regions, with Asia-Pacific showing rapid growth.

FAQs

What is vecuronium bromide used for?

Vecuronium bromide is used as a neuromuscular blocker during general anesthesia to facilitate endotracheal intubation and surgical relaxation, and in intensive care settings to achieve paralysis for mechanical ventilation[2].

Who are the main players in the vecuronium bromide market?

The main players include Jiupai Group, Credit Chemwerth Pharmaceutical, Beijing Xinze Medical Technology, Xianju Pharma, Jiangsu Nhwa Pharmaceutical, Curia, and Teva API[1][4].

What are the key segments of the vecuronium bromide market?

The market is segmented by type (≥ 98% and < 98%) and application (surgery and tracheal intubation)[1][4].

How has the COVID-19 pandemic affected the vecuronium bromide market?

The pandemic had a mixed impact, disrupting supply chains but also increasing demand for critical care services, which boosted the need for vecuronium bromide[1].

What are the key growth drivers for the vecuronium bromide market?

Key drivers include increasing demand in medical sectors, technological advancements, and compliance with environmental and safety regulations[1].

Sources

  1. Global Vecuronium Bromide Market Report 2024 Edition - Cognitivemarketresearch.com
  2. Vecuronium - StatPearls - NCBI Bookshelf - Ncbi.nlm.nih.gov
  3. Antimicrobial Drugs Market Returns Analysis - Aspe.hhs.gov
  4. Global Vecuronium Bromide Market Research Report 2024 - Valuates.com

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.